ES2152671T3 - Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales. - Google Patents

Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.

Info

Publication number
ES2152671T3
ES2152671T3 ES97923523T ES97923523T ES2152671T3 ES 2152671 T3 ES2152671 T3 ES 2152671T3 ES 97923523 T ES97923523 T ES 97923523T ES 97923523 T ES97923523 T ES 97923523T ES 2152671 T3 ES2152671 T3 ES 2152671T3
Authority
ES
Spain
Prior art keywords
rent
selected member
treat
group formed
aciloxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97923523T
Other languages
English (en)
Spanish (es)
Inventor
Hyun K Kim
Richard P Blye
Pemmaraju N Rao
James W Cessac
Carmie K Acosta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2152671T3 publication Critical patent/ES2152671T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES97923523T 1996-05-01 1997-04-30 Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales. Expired - Lifetime ES2152671T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1662896P 1996-05-01 1996-05-01

Publications (1)

Publication Number Publication Date
ES2152671T3 true ES2152671T3 (es) 2001-02-01

Family

ID=21778122

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97923523T Expired - Lifetime ES2152671T3 (es) 1996-05-01 1997-04-30 Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.

Country Status (13)

Country Link
US (4) US6861415B2 (enExample)
EP (1) EP0900234B1 (enExample)
JP (1) JP4260886B2 (enExample)
AT (1) ATE194358T1 (enExample)
AU (1) AU710139B2 (enExample)
CA (2) CA2668824A1 (enExample)
DE (1) DE69702450T2 (enExample)
DK (1) DK0900234T3 (enExample)
ES (1) ES2152671T3 (enExample)
GR (1) GR3034562T3 (enExample)
HU (1) HU230492B1 (enExample)
PT (1) PT900234E (enExample)
WO (1) WO1997041145A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
CZ2002704A3 (cs) * 1999-08-31 2003-02-12 Jenapharm Gmbh & Co. Kg Použití mesoprogestinů (modulátorů receptoru pro progesteron) pro výrobu léků k léčení a prevenci benigních gynekologických onemocnění závislých na hormonech
US6740645B1 (en) * 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
US6768014B2 (en) 1999-12-29 2004-07-27 The United States Of America As Represented By The Department Of Health And Human Services PROCESS FOR PREPARING 17α-ACETOXY-11β-[4-N,N(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS , AND PROCESSES FOR PREPARING SUCH INTERMEDIATES
DK1265911T3 (da) * 2000-03-17 2008-09-29 Us Gov Health & Human Serv 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler
MXPA02010066A (es) * 2000-04-12 2003-06-04 Schering Ag Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos.
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
US8044223B2 (en) * 2003-04-04 2011-10-25 Bridge Organics Co. Crystalline 19-norsteroids
DE602005026290D1 (de) * 2004-07-09 2011-03-24 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
US20070010626A1 (en) * 2005-07-11 2007-01-11 Shankernarayanan Manivakkam J Polyethylene compositions
AU2006294449A1 (en) * 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
KR20090067198A (ko) 2006-10-24 2009-06-24 레프로스 쎄라피우틱스 아이엔씨. 자궁내막 증식을 억제하는 조성물과 방법
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
EP2094275A2 (en) * 2006-12-28 2009-09-02 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
HUE029397T2 (en) * 2007-04-20 2017-03-28 Preglem Sa Selective progesterone modulators for treating uterine bleeding
HU228636B1 (en) 2007-06-27 2013-04-29 Richter Gedeon Nyrt Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
US20090118253A1 (en) * 2007-11-05 2009-05-07 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TW201002736A (en) * 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
HUP0900171A2 (hu) * 2009-03-20 2010-12-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos módosulata és eljárás elõállítására
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
WO2011119194A1 (en) * 2010-03-22 2011-09-29 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2664325A1 (en) * 2012-05-16 2013-11-20 PregLem S.A. Methods for preventing or treating androgen mediated diseases
MX363640B (es) 2012-05-31 2019-03-28 Repros Therapeutics Inc Formulaciones y metodos para la administracion vaginal de antiprogestinas.
CN103772468B (zh) * 2012-10-19 2017-04-05 华润紫竹药业有限公司 醋酸特拉司酮及其中间体的制备方法和用途
ES2688821T3 (es) 2012-11-02 2018-11-07 Repros Therapeutics Inc. Métodos y composiciones para tratar afecciones dependientes de la progesterona
HU230319B1 (hu) * 2013-10-01 2016-01-28 Richter Gedeon Nyrt. Ipari eljárás szteroid hatóanyagok előállítására
CN104774233A (zh) * 2014-01-13 2015-07-15 上海医药工业研究院 3-(亚乙二氧基)-17β-氰基-17α-三甲基硅氧基-雌-5(10),9(11)-二烯的制备工艺
HU230381B1 (hu) 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
DE202020102472U1 (de) * 2020-05-04 2020-12-09 Disphar International Bv Orale Form von Mifepriston zur Verwendung bei Zervixreifung und Geburtseinleitung

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3381003A (en) * 1965-06-01 1968-04-30 Merck & Co Inc 3-keto-13beta-alkyl-17beta-acetyl-gona-4-ene-17alpha-ol compounds and processes of preparing them
DE2727368A1 (de) 1977-06-14 1979-01-04 Schering Ag Kortikoide, verfahren zu deren herstellung und pharmakoligische praeparate auf deren basis
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
ES533260A0 (es) 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
DE3321826A1 (de) 1983-06-15 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
AU558725B2 (en) 1983-09-07 1987-02-05 Mitsubishi Kasei Corporation Corticoid derivatives
DE3504421A1 (de) 1985-02-07 1986-08-07 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 11ss-phenyl-gonane, deren herstellung und diese enthaltende pharmazeutische praeparate
AU580843B2 (en) 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3761308D1 (de) 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5272140A (en) 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
DE3736509A1 (de) * 1987-10-28 1989-05-11 Hoechst Ag Vorrichtung zum laminieren und schneiden von fotoresistbahnen
EP0321010B1 (en) 1987-12-12 1993-02-03 Akzo N.V. New 11-arylsteroid compounds
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
DE3832303A1 (de) * 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
US5364847A (en) 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
JP3135564B2 (ja) * 1989-08-04 2001-02-19 シエーリング アクチエンゲゼルシヤフト １１β―置換１６α，１７α―メチレン―エストラ―４，９―ジエン―３―オン
DD289541A5 (de) * 1989-08-04 1991-05-02 ��@�K@�������������@�K@��������������@��������k�� Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
DE4042004A1 (de) 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
WO1995004536A1 (en) * 1993-08-04 1995-02-16 Akzo Nobel N.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
US5604822A (en) * 1993-11-12 1997-02-18 Martin Marietta Corporation Methods and apparatus for centroid based object segmentation in object recognition-type image processing system
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.

Also Published As

Publication number Publication date
US20100113408A1 (en) 2010-05-06
WO1997041145A1 (en) 1997-11-06
US6861415B2 (en) 2005-03-01
EP0900234B1 (en) 2000-07-05
DE69702450T2 (de) 2001-03-08
US8003629B2 (en) 2011-08-23
PT900234E (pt) 2000-12-29
US20050143364A1 (en) 2005-06-30
EP0900234A1 (en) 1999-03-10
CA2253673A1 (en) 1997-11-06
AU2930497A (en) 1997-11-19
US7087591B2 (en) 2006-08-08
HUP9903515A3 (en) 2000-04-28
HUP9903515A2 (hu) 2000-03-28
CA2253673C (en) 2009-09-08
ATE194358T1 (de) 2000-07-15
JP2000509396A (ja) 2000-07-25
JP4260886B2 (ja) 2009-04-30
CA2668824A1 (en) 1997-11-06
DK0900234T3 (da) 2000-11-06
US20020025951A1 (en) 2002-02-28
US20060276443A1 (en) 2006-12-07
DE69702450D1 (de) 2000-08-10
AU710139B2 (en) 1999-09-16
HU230492B1 (hu) 2016-08-29
US7759330B2 (en) 2010-07-20
GR3034562T3 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
ES2152671T3 (es) Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
DK0538443T3 (da) Fremgangsmåde og formuleringer til kontraception og til behandling af godartede gynækologiske forstyrrelser
BR9908338A (pt) Método, composição e dispositivo para a regulação do cio e da ovulação em matrizes
ES2164758T3 (es) Derivados de morfolina sustituidos y su uso como agentes terapeuticos.
ES2172579T3 (es) Agonistas/antagonistas de estrogenos.
ES2128629T3 (es) Derivados de bencilpiperidina con afinidad elevada a puntos de enlace de receptores de aminoacidos.
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
ES2176329T3 (es) Procedimientos para preparar formas anhidras e hidratadas de derivados antihistaminicos de piperidina, sus polimeros y pseudomorfos.
CY1105957T1 (el) Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης
AR026052A1 (es) Derivados de purina
ES2114605T5 (es) Metodo anticonceptivo que emplea un antagonista de progesterona competitivo y nuevos compuestos utilizados en el.
ATE264106T1 (de) Verfahren zur empfängnisverhütung
IL152248A0 (en) 8beta-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS
PE10997A1 (es) NUEVOS DERIVADOS DE [3-(4-FENILPIPERACIN-1-i1)PROPILAMINO]-PIRIDINA, PIRIMIDINA Y BENCENO COMO ANTAGONISTAS DE a1-ADRENOCEPTORES, SUS EMPLEOS COMO AGENTES TERAPEUTICOS Y LOS METODOS PARA SU PREPARACION
BR0316843A (pt) Derivados tetracìclicos contendo heteroátomo como moduladores seletivos do receptor de estrogênio
AR053596A1 (es) Forma polimorfa ii de tanaproget
PE20060853A1 (es) 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
ES2148858T3 (es) (aminoalquil- y acilaminoalquil-oxi)benciloxiquinolinas, procedimiento para su preparacion y su empleo como antagonistas de receptores de bradiquinina.
DK1082129T3 (da) Fremgangsmåde til behandling af fertilitetsdefekt
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
ES2070002T3 (es) Composiciones terapeuticas a base de derivados de 1,2-ditiol-3-tiona.
ES2164400T3 (es) Esteroides con actividad anticonceptiva y antiosteoporotica.
ES2154902T3 (es) Derivados de la n-bis o n-tris-((1,2-dicarboxi-etoxi)-etil)-amina y a la preparacion y empleo de los mismos.
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 900234

Country of ref document: ES